Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board changes and issue of options

1 Feb 2017 07:00

RNS Number : 6565V
Byotrol PLC
01 February 2017
 

 

1 February 2017

 

Byotrol plc

 

("Byotrol" or the "Company")

 

Board changes and issue of options

 

 

Byotrol plc, the specialist anti-microbial technology company, is pleased to announce that John Langlands has been appointed as Chairman with effect from today's date and that Nicholas Martel has stepped down as Chairman and as a Director, also with effect today. Nicholas will remain with the Company for a further three months to ensure an orderly hand-over.

 

John Langlands has considerable business, commercial and City experience having worked for a number of listed companies. He has been CEO since 2003 of British Polythene Industries Plc, a leading European producer of polythene films for packaging and agriculture. BPI was sold to RPC GROUP Plc in August 2016 and John left BPI at the end of January 2017 following the successful integration of BPI into RPC.

 

Mr. Langlands is also being awarded options over 2,700,000 ordinary shares of 0.25p each ("Options" and "Ordinary Shares") as part of the Company's Unapproved Share Option Scheme (the "Award"). The Options have an exercise price of 4.125p, being the closing mid-market share price on 31 January 2017, vest immediately and expire on 14 October 2021. Following the Award there are now 33,757,500 options over Ordinary Shares representing 12.59 per cent. of the existing issued share capital of the Company.

 

Mr Langlands holds 300,000 ordinary shares in Byotrol, representing 0.1% of the Company's issued share capital.

 

Nicholas Martel comments:

 

"After three enjoyable years as Chairman, I look forward to resuming my previous role of supportive shareholder. I am delighted that John has been appointed as my successor and that he will be leading the next phase of Byotrol as we commercialise our new technologies. With a strong team in place and with the recent progress on our three key projects, Byotrol is well positioned for further growth. John knows Byotrol well already and brings a wealth of relevant business experience across many countries and industries."

 

David Traynor, Chief Executive, comments:

 

"We are very grateful to Nicholas for his calm and steady oversight of Byotrol over four years as a NED, three of which as Chairman. We will all miss his insight and support.

 

The Byotrol team is very much looking forward to working with John. He has first-class industry expertise, City experience and all-round business acumen, including in M&A. We are really pleased to welcome him to our Board." 

The following further details are given in accordance with Rule 17 and Schedule 2 (g) of the AIM Rules for Companies:

John Thomson Langlands (age 64)

Current directorships or partnerships: Maven Capital (Telfer House) LLP

Previous directorships or partnerships in the past 5 years:

British Polythene Industries Limited (formerly British Polythene Industries PLC)

 

British Polythene Limited

 

BPI Limited

 

Scott and Robertson Limited

 

BPI Employees trust Limited

 

Flexfilm Limited

 

Jordan Plastics Limited

There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

Enquiries:

Byotrol plc

01925 742 000

David Traynor - Chief Executive

 

 

 

finnCap Ltd

 

020 7220 0500

(Nominated Adviser & Broker)

 

Geoff Nash/Carl Holmes/James Thompson - Corporate Finance

 

Mia Gardner - Corporate Broking

 

 

 

Notes to Editors:

Byotrol plc (BYOT.L), quoted on AIM, is a specialist in developing, formulating and commercialising cutting-edge antimicrobial technologies.

Our patented suite of technologies delivers powerful broad-spectrum efficacy with residual performance optimised against commonly occurring and industry-specific pathogens.

 

Founded in 2005, the Company has developed the technology that creates easier, safer and cleaner lives. For more information, please go to www.byotrol.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDFLFXDFFLBBD
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.